atai Life Sciences CEO details 2025 progress and upcoming milestones

Proactive - Interviews for investors

atai Life Sciences CEO and co-founder Dr Srinivas Rao talked with Proactive's Stephen Gunnion about the company’s clinical development progress in 2025, highlighting multiple upcoming trial readouts. He discussed new data from Beckley Psytech’s Phase 2a trial of BPL-003, a psychedelic compound being evaluated in patients already taking SSRIs. Rao confirmed the trial showed “very good safety and tolerability and very robust efficacy,” with results from a broader Phase 2b trial expected mid-year. Rao also detailed progress on RL-007, a candidate targeting cognitive impairment in schizophrenia, which is also in Phase 2b. He added that VLS-01 (Illumina study) and EMP-01 for social anxiety disorder will report data early in 2026. EMP-01 is being trialed in a six-week study with two administrations, using the Liebowitz Social Anxiety Scale as the primary endpoint. “We wanted to go after a different indication — there’s really no one focused on social anxiety disorder currently with a psychedelic compound,” Rao said, underlining the novelty of their approach. Rao further noted investor interest in broader industry readouts, including those from Compass, in which atai remains a shareholder. For more updates from atai Life Sciences and other biotech innovators, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications for future content. #ataiLifeSciences #PsychedelicTherapy #ClinicalTrials #MentalHealthInnovation #BPL003 #EMP01 #SocialAnxietyDisorder #BiotechNews #PharmaUpdates #RL007 #VLS01 #FDAApprovalPath #ProactiveInvestors #Biotech2025 #SSRI